Skip to main content

Table 3 Correlation between immunohistochemistry scores for hormone receptors and response to endocrine therapy in breast cancer

From: Phosphorylation of estrogen receptor α serine 167 is predictive of response to endocrine therapy and increases postrelapse survival in metastatic breast cancer

Receptor

Responders (n = 35)a

Nonresponders (n = 40)a

P b

P c

ER-α (1D5)

5.8 ± 2.3 (7; 0–8)

4.1 ± 2.9 (5; 0–8)

0.0045*

0.0046*

ER-α Ser118

4.3 ± 2.6 (5; 0–8)

4.2 ± 2.4 (4; 0–8)

0.90

0.96

ER-α Ser167

2.5 ± 2.0 (2; 0–6)

1.6 ± 1.7 (2; 0–5)

0.033*

0.025*

ER-β1

4.2 ± 2.2 (4; 0–8)

4.5 ± 2.3 (5; 0–8)

0.43

0.57

ER-βcx/β2

3.1 ± 2.4 (3; 0–8)

3.0 ± 2.5 (2; 0–8)

0.72

0.80

PR (636)

5.5 ± 2.5 (6; 0–8)

3.6 ± 2.7 (4; 0–8)

0.0008*

0.0014*

PRA

4.6 ± 2.0 (5; 0–8)

2.4 ± 2.5 (2; 0–8)

0.0001*

<0.0001*

PRB

4.0 ± 2.1 (4; 0–8)

2.7 ± 2.4 (3; 0–8)

0.013*

0.015*

  1. aValues are means ± standard deviations (medians; ranges). bMann–Whitney U test. cUnpaired t-test. *P <0.05. ER, estrogen receptor; PR(A,B), progresterone receptor (A,B).